Triumeq

Active Ingredient(s): Abacavir Sulfate + Dolutegravir + Lamivudine
FDA Approved: * August 22, 2014
Pharm Company: * VIIV HLTHCARE
Category: HIV / AIDS

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Triumeq Overview

Abacavir/dolutegravir/lamivudine (brand name Triumeq) is a fixed-dose combination medication for the treatment of HIV/AIDS. It is a combination of three medications with different and complementary mechanisms of action: 600mg abacavir (reverse transcriptase inhibitor), 50mg dolutegravir (integrase inhibitor) and 300mg lamivudine (nucleoside analog reverse transcriptase inhibitor). The medication was developed by ViiV Healthcare and approved by the Food and Drug Administration for use in the ...

Read more Triumeq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Triumeq

Recent Triumeq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Abacavir Sulfate + Dolutegravir + Lamivudine
  • Tablet: 600mg + 50mg + 300mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Triumeq: (3 results)

Sorted by National Drug Code
  • 49702-231 Triumeq Oral Tablet, Film Coated by Viiv Healthcare Company
  • 50090-1606 Triumeq Oral Tablet, Film Coated by A-s Medication Solutions
  • 54569-6569 Triumeq Oral Tablet, Film Coated by A-s Medication Solutions

Drugs with one or more similar ingredients: (24 results)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 17 February 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA